Inhibition non competitive

The non-competitive inhibitor is not bound to the active site of the enzyme but to some other site. Therefore, the inhibitor can react equally with free enzyme or with enzyme-substrate complex. Thus, three processes occur in parallel  

Postulating that EAI and FI are catalytically inactive and the dissociation constants Ki and Keai are numerically equal, the following equation is obtained by rearrangement of the equation for a single-substrate reaction into its reciprocal form  

The double-reciprocal plot (Fig. 2.30b) shows that, in the presence of a noncompetitive inhi- 

This also indicates that, in the presence of inhibitor, the amount of enzyme available for catalysis is decreased. 

A classic non-competitive inhibitor has no effect on substrate binding and vice-versa. Inhibitor and substrate molecules adsorb independently on different sites but, while the inhibitor does not affect the adsorption of the substrate it does inhibit the further reaction of the adsorbed species. On a metal catalyst this type of inhibition could arise when the substrate is adsorbed on a comer atom and the inhibitor on face atoms near the comer. The resulting steric or electronic factors could prevent further reaction of the adsorbed substrate. 

The equations showing non-competitive inhibition are given in Eqn. 7.32. According to this series of equilibria, at any concentration of I some of the active sites will have both an adsorbed S and a neighboring I, an arrangement which is non-reactive. In this case the V ,ax of the reaction will decrease. 

The reciprocal form of the rate equation for Eqn. 7.32 is given in Eqn. 7.33 with both the slope and the y-axis intercept modified by Vn,a,j(apparent) which is defined in Eqn. 7.34. 

Plots of 1/v versus 1/ S] at various concentrations of I are shown in Fig. 7.8. This type of plot with all of the lines intersecting the x-axis at the same point, -1/K[vi, is characteristic of reactions run with non-competitive inhibition. The 

The replot of the slopes versus [I] has an x-axis intercept of -K. The y-axis intercept is K]v A max which is the slope of the reaction plot at [I = 0. The slope of the replot is equal to the slope of the uninhibited reaction multiplied by 1/K,. 

Dissociation constant of the El-complex with release of 1 Dissociation constant of the ESI-complex with release of I Dissociation constant of the ESI-complex with release of S 

For ordinary non-competitive inhibition, the Ki and Kis values are identical and also the Ks and Ks1 values. In this case rate equation (30) is valid  

Compared to Eq. (27), the rate equation for non-competitive inhibitor includes another term for the equilibrium of decomposition of the ESI-complex into E, S and I. 

From Eq. (31) it can be concluded that a non-competitive inhibitor has no effect on the Ks value but lowers the umax value. This is because the inhibitor binds all enzyme species with the same affinity. 

---

The three most common types of inhibitors in enzymatic reactions are competitive, non-competitive, and uncompetitive. Competitive inliibition occurs when tlie substrate and inhibitor have similar molecules that compete for the identical site on the enzyme. Non-competitive inhibition results in enzymes containing at least two different types of sites. The inhibitor attaches to only one type of site and the substrate only to the other. Uncompetitive inhibition occurs when the inhibitor deactivates the enzyme substrate complex. The effect of an inhibitor is determined by measuring the enzyme velocity at various... 

In such inhibition, the inhibitor and die substrate can simultaneously bind to the enzyme. The nature of the enzyme-inhibitor-substrate binding has resulted in a ternary complex defined as EIS. The Ks and Kt are identical to the corresponding dissociation constants. It is also assumed that the EIS does not react further and is unable to deliver any product P. The rate equation for non-competitive inhibition, unvAX, is influenced ... 

In non-competitive inhibition, the substrate (S) and inhibitor (I) have equal potential to bind to the free enzyme (E). The inhibitor forms a ternary complex with enzyme-substrate (ES) whereas the substrate will form another ternary complex with enzyme-inhibitor (El). Since the non-competitive inhibitor had no effect on the binding of substrate to the enzyme, the Km value remained consistent (or unchanged). There are two different ways for the formation of ESI ternary complex this complex would not form the product and therefore was decreased. Non-competitive inhibitor had no effect on substrate binding or the enzyme-substrate affinity, therefore the apparent rate constant (K ) was unchanged.5 A possible reason for product inhibition was because of the nature of 2-ethoxyethanol,... 

Following concurrent administration of two drugs, especially when they are metabolized by the same enzyme in the liver or small intestine, the metabolism of one or both drugs can be inhibited, which may lead to elevated plasma concentrations of the dtug(s), and increased pharmacological effects. The types of enzyme inhibition include reversible inhibition, such as competitive or non-competitive inhibition, and irreversible inhibition, such as mechanism-based inhibition. The clinically important examples of drug interactions involving the inhibition of metabolic enzymes are listed in Table 1 [1,4]. 

The cases of non-competitive inhibition and even more complex non-linear reaction kinetics will not be discussed further here. 

Donepezil is a piperidine cholinesterase inhibitor, which reversibly and non-competitively inhibits centrally active acetylcholinesterase 34 This specificity is claimed to result in fewer peripheral side effects as compared to the other ChE inhibitors. 

ARRY-438162 is a recently disclosed potent and selective ATP non-competitive MEK1/2 inhibitor that is in Phase lb clinical trials as an anti-arthritic agent [24]. ARRY-438162 inhibited the MEK1/2 enzyme with an IC50 = 12 nM and pERK in cells with an IC50 = 11 nM. ATP non-competitive inhibition may be responsible for equipotent inhibition of MEK1/2 in vitro and pERK in cells. The compound was selective against a panel of 220 other kinases. 

Reversible, non-competitive inhibition of polymerase is also afforded by a series of N-benzoyl pyrrolidines. Substitution on the benzoyl moiety with a para-trifluoromethyl group is optimal in this series. Bulky, hydrophobic groups at the 2-position of the pyrrolidine ring increase activity, and the 5-position tolerates a wide range of substituents, indicative of a solvent exposed portion of the inhibitor. Compound (+)-38, containing a 2-thienyl moiety at the 5-position, has an IC50 of 190 nM in the enzyme assay while its enantiomer is almost 100-fold less active [83]. 

C7. Crane, R. K., and Sols, A., The non-competitive inhibition of brain hexokinase by glucose-6-phosphate and related compounds. J. Biol. Chem. 210, 597-606 (1954). 

Another type of inhibitor combines with the enzyme at a site which is often different from the substrate-binding site and as a result will inhibit the formation of the product by the breakdown of the normal enzyme-substrate complex. Such non-competitive inhibition is not reversed by the addition of excess substrate and generally the inhibitor shows no structural similarity to the substrate. Kinetic studies reveal a reduced value for the maximum activity of the enzyme but an unaltered value for the Michaelis constant (Figure 8.7). There are many examples of non-competitive inhibitors, many of which are regarded as poisons because of the crucial role of the inhibited enzyme. Cyanide ions, for instance, inhibit any enzyme in which either an iron or copper ion is part of the active site or prosthetic group, e.g. cytochrome c oxidase (EC 1.9.3.1). 

Use the data in the table above to plot Michaelis-Menten, Lineweaver-Burke and Eadie-Hofstee graphs to determine Km and Vm DC values. State the type of inhibitor which is present. Calculate the K based on Equations 2.10 (for competitive inhibition) or 2.11 (non-competitive inhibition) asappropriate assuming the [I] = 10mmol/l. 

Friese J, Gleitz J. (1998). Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3FI]-batrachotoxinin-A 20-alpha-... 

Tian, G., Sobotka-Biiner, C.D., Zysk, J., et al. (2002) Linear non-competitive inhibition of solubilized human y-secretase by pepstatin A methylesper, L685458, sulfonamides, and benzodiazepines. J. Biol. Chem., 277, 31499-31505. 

These equilibrium-binding relationships give rise to four different kinetic responses competitive inhibition, uncompetitive inhibition, non-competitive inhibition, mixed inhibition. Details of the kinetics of these types of inhibition and how dissociation constants for the reactions can be measured are provided in Appendix 3.6. 

U nder assay conditions whereby the concentration of the probe substrate is equivalent to Km, an IC50 estimate is equivalent to twofold K. For non-competitive inhibition, Kj is equivalent to IC50 since inhibitor and substrate binding are independent... 

If the effect of an inhibitor on an enzyme is to be investigated, the Dixon plot is recommended. To obtain data for the Dixon plot, estimate the reaction rate at constant substrate concentration and vary the inhibitor concentration [I]. At competitive inhibition, all the obtained straight lines coincide at a point with the coordinates X = -Ki, y = 1/Vmax> and at non-competitive inhibition all the straight lines have the same intercept on abscissa at x = -Ki. At... 

The extract produced an inhibition of 5-aRl and 5-aR2 activities in the presence of free fatty (oleic, lauric, linoleic, and myris-tic) acids only. Esterified fatty acids, alcohols, and sterols assayed were inactive. A specificity of the fatty acids in 5-aRl or 5-aR2 inhibition has been found. Palmitic and stearic acids were inactive on the two isoforms. Lauric acid was active on 5-aRl (lC5o= 17 + 3 iig/mL) and5-aR2 (lC5o= 19 + 9 p,g/mL). The inhibitory activity of myristic acid was evaluated on 5-aR2 only and found active on this isoform (IC50 = 4 2 p,g/mL) ° . LSESr markedly inhibited both isozymes (Kj [type 1] = 8.4 nM and 7.2 p,g/mL, respectively Kj [type 2] = 7.4 nM and 4.9 iig/mL, respectively). Results indicated that LSESr displayed non-competitive inhibition of the type 1 isozyme and uncompetitive inhibition of the type 2 isozyme . 

Rubben, and M. C. Michel. Saw palmetto extracts potently and non-competitively inhibit human alphal- SR073 adrenoceptors in vitro. Prostate 1999 ... 

A non-competitive inhibitor causes an apparent fall in the amount of enzyme present, irrespective of the concentration of the substrate. In purely non-competitive inhibition, Km does not alter. 

Compound 2 inhibited murine and human bone marrow cell colony formation with and ID50 of 0.1-1 pg/ml, with complete inhibition occurring at 10-100 pg/ml. It was found to be more potent than vinblastine or taxol, with an IC50 of 0.23 nM against human ovarian cancer and colon cancer cell lines. Furthermore, dolastatin 10 was shown to be powerfully effective at binding to tubulin, inhibiting polymerization and it also non-competitively inhibits the binding of vinca alkaloids to tubulin,... 

Reversible inhibition occurs rapidly in a system which is near its equilibrium point and its extent is dependent on the concentration of enzyme, inhibitor and substrate. It remains constant over the period when the initial reaction velocity studies are performed. In contrast, irreversible inhibition may increase with time. In simple single-substrate enzyme-catalysed reactions there are three main types of inhibition patterns involving reactions following the Michaelis-Menten equation competitive, uncompetitive and non-competitive inhibition. Competitive inhibition occurs when the inhibitor directly competes with the substrate in forming the enzyme complex. Uncompetitive inhibition involves the interaction of the inhibitor with only the enzyme-substrate complex, while non-competitive inhibition occurs when the inhibitor binds to either the enzyme or the enzyme-substrate complex without affecting the binding of the substrate. The kinetic modifications of the Michaelis-Menten equation associated with the various types of inhibition are shown below. The derivation of these equations is shown in Appendix S.S. 

In mixed inhibition, a second assumption in the derivation of non-competitive inhibition must be made—that the binding of the substrate and the inhibitor to the... 

Non-competitive inhibition is more complicated than either competitive or uncompetitive inhibition. A non-competitive inhibitor can combine with an enzyme molecule to produce a dead-end complex regardless of whether a substrate molecule is bound or not. Hence the inhibitor must bind at a different... 

Even this scheme represents a complex situation, for ES can be arrived at by alternative routes, making it impossible for an expression of the same form as the Michaelis-Menten equation to be derived using the general steady-state assumption. However, types of non-competitive inhibition consistent with the Michaelis-Menten type equation and a linear Linweaver-Burk plot can occur if the rapid-equilibrium assumption is valid (Appendix S.A3). In the simplest possible model, involving simple linear non-competitive inhibition, the substrate does not affect the inhibitor binding. Under these conditions, the reactions... 

The Lineweaver-Burk equation for simple linear non-competitive inhibition is ... 

Figure S.14 shows a plot of such an inhibition pattern. There are few clear-cut examples of non-competitive inhibition of a single-substrate reaction, as might be expected from this special case. Normally the inhibitor constants in Scheme S.AS.3 are different.

Non-competitive, uncompetitive and mixed inhibitions occur when both the inhibitor and the substrate bind simultaneously to the enzyme and do not compete for the same binding site as in competitive inhibition (Scheme 11.20). Non-competitive inhibition occurs when Km = Klu (i.e. the dissociation constant of S from EIS is the same as that from ES) and... 

Non-competitive inhibition is indicated by an Eadie-Hofstee plot with parallel lines (Fig. 11.13A). 

In Table II are shown the results from kinetic studies with commercially available gastric and pancreatic enzymes. Trypsin was strongly inhibited, at least at a low concentration of casein as substrate. The hydrolysis of benzoyl arginine ethyl ester (BAEE) by trypsin was non-competitively inhibited, giving a 30% reduction of Vmax at 0.5 mg/ml of the LMW fraction. Carboxypepti-dase A, and to a lesser extent carboxypeptidase B, were non-competitively inhibited as well. Pepsin and chymotrypsin were not affected by the conditions used in these assays. 

Carboxypepti-dase A N.-Benzoyl-GLYPHE 0.5 Non-competitive inhibition. Vm, reduced 30%. max... 

Composite figure for the two /3-D-glucosiduronic acid groups in the glycyrrhizinic acid molecule there is, in addition, an element of non-competitive inhibition with this di-D-glucosiduronic acid. 

Non-competitive inhibitors bind reversibly to an allosteric site (see Appendix 7) on the enzyme. In pure non-competitive inhibition, the binding of the inhibitor to the enzyme does not influence the binding of the substrate to the enzyme. However, this situation is uncommon, and the binding of the inhibitor usually causes conformational changes in the structure of the enzyme, which in turn affects the binding of the substrate to the enzyme. This is known as mixed noncompetitive inhibition. The fact that the inhibitor does not bind to the active site of the enzyme means that the structure of the substrate cannot be used as the basis of designing new drugs that act in this manner to inhibit enzyme action. 

---